Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil

Clinical Genetics

Volumn 62, Issue 1, 2002, Pages 45-52

  Bosse Y ^a   Vohl, M C ^b,c   Dumont, M ^a   Brochu, M ^d   Bergeron, J ^b   Despres J P ^b,c   Prud'homme, Denis ^e  

^a Dept of Social/Preventive Med   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

ACE I D polymorphism; Gemfibrozil; HDL cholesterol; Visceral obesity

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ALLELE; ANALYSIS OF VARIANCE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DYSLIPIDEMIA; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN INTERACTION; RECURRENCE RISK;

ADMINISTRATION, ORAL; ADULT; ANTILIPEMIC AGENTS; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIPOPROTEINS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; SEQUENCE DELETION; TREATMENT OUTCOME;

INSERTION SEQUENCES;

EID: 0036665063     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2002.620106.x     Document Type: Article

References (52)

1. Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc 1988: 260 (5): 641-651.
2. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New Engl J Med 1999: 341 (6): 410-418.
3. Despres JP, Moorjani S, Tremblay A et al. Heredity and changes in plasma lipids and lipoproteins after short-term exercise training in men. Arteriosclerosis 1988: 8 (4): 402-409.
4. Ordovas JM, Lopez-Miranda J, Mata P et al. Gene-diet interaction in determining plasma lipid response to dietary intervention. Atherosclerosis 1995: 118 (Suppl): S11-S27.
5. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992: 13 (12): 434-439.
6. Aalto-Setälä K, Kontula K, Manttari M et al. DNA polymorphisms of apolipoprotein B and AI/CIII genes and response to gemfibrozil treatment. Clin Pharmacol Ther 1991: 50 (2): 208-214.
7. Marian AJ, Safavi F, Ferlic L et al. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 2000: 35 (1): 89-95.
8. Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990: 86 (4): 1343-1346.
9. Turner ST, Boerwinkle E, Sing CF. Context-dependent associations of the ACE I/D polymorphism with blood pressure. Hypertension 1999: 34 (4 Part 2): 773-778.
10. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996: 94 (4): 708-712.
11. Schunkert H. Controversial association of left ventricular hypertrophy and the ACE I/D polymorphism - is the mist clearing up? Nephrol Dial Transplant 1998: 13 (5): 1109-1112.
12. Bauters C, Amouyel P, Bertrand ME. ACE gene polymorphism and coronary restenosis. Semin Interv Cardiol 1999: 4 (3): 145-149.
13. Marre M, Hadjadj S, Bouhanick B. Hereditary factors in the development of diabetic renal disease. Diabetes Metab 2000: 26 (Suppl 4): 30-36.
14. Amouyel P, Richard F, Berr C, David-Fromentin I, Helbecque N. The renin angiotensin system and Alzheimer's disease. Ann New York Acad Sci 2000: 903: 437-441.
15. Woods DR, Humphries SE, Montgomery HE. The ACE I/D polymorphism and human physical performance. Trends Endocrinol Metab 2000: 11 (10): 416-420.
16. Okamura A, Ohishi M, Rakugi H et al. Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty. Angiology 1999: 50 (10): 811-822.
17. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000: 35 (1): 60-66.
18. Suzuki T, Yokota H, Yamazaki T et al. Angiotensin converting enzyme polymorphism is associated with severity of coronary heart disease and serum lipids (total cholesterol and triglyceride levels) in Japanese patients. Coron Artery Dis 1996: 7 (5): 371-375.
19. Oren I, Brook JG, Gershoni-Baruch R et al. The D allele of the angiotensin-converting enzyme gene contributes towards blood LDL-cholesterol levels and the presence of hypertension. Atherosclerosis 1999: 145 (2): 267-271.
20. Badenhop RF, Wang XL, Wilcken DE. Angiotensin-converting enzyme genotype in children and coronary events in their grandparents. Circulation 1995: 91 (6): 1655-1658.
21. Kobayashi K, Amemiya S, Mochizuki M et al. Association of angiotensin-converting enzyme gene polymorphism with lipid profiles in children and adolescents with insulin-dependent diabetes mellitus. Horm Res 1999: 51 (4): 201-204.
22. Pamies Andreu E, Palmero C, Garcia Lozano R et al. The effect of the angiotensinogen M235T and the angiotensin-converting enzyme I/D polymorphisms on arterial hypertension and other cardiovascular risk factors. Med Clin (Barcelona) 1999: 113 (5): 164-168.
23. Berge KE, Berg K. Cardiovascular risk factors in people with different genotypes in the insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme (ACE). Clin Genet 1997: 52 (6): 422-426.
24. Scheidegger KJ, Butler S, Witztum JL. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem 1997: 272 (34): 21609-21615.
25. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994: 107 (1): 71-84.
26. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996: 16 (1): 97-105.
27. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993: 290 (1): 33-40.
28. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974: 20 (4): 470-475.
29. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982: 28 (10): 2077-2080.
30. Havel RJ, Eder H, Bragdon HF. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955: 34: 1345-1353.
31. Burstein M, Samaille J. Sur un dosage rapide du cholestérol lié aux B-lipoprotéines du sérum. Clin Chim Acta 1960: 5: 609.
32. Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982: 23 (8): 1206-1223.
33. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966: 15 (1): 45-52.
34. Moorjani S, Dupont A, Labrie F et al. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism 1987: 36 (3): 244-250.
35. Behnke AR, Wilmore JH. Evaluation and Regulation of Body Build and Composition. Englewood Cliffs, NJ: Prentice Hall, 1974.
36. Meneely GRK, Kaltreider NL. Volume of the lung determined by helium dilution. J Clin Invest 1949: 28: 129-139.
37. Siri WE. The gross composition of the body. Adv Biol Med Phys 1956: 4: 239-280.
38. The Airlie (VA) Consensus Conference. In: Lohman T, Roche A, Martorel R, eds. Standardization of anthropometric measurements. Champaign, IL: Human Kinetics, 1988: 39-80.
39. Evans AE, Poirier O, Kee F et al. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. Q J Med 1994: 87 (4): 211-214.
40. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl 1993: 3 (2): 120-121.
41. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992: 20 (6): 1433.
42. Rubins HB, Robins SJ, Iwane MK et al. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 1993: 71 (1): 45-52.
43. Lusis AJ. Genetic factors affecting blood lipoproteins: the candidate gene approach. J Lipid Res 1988: 29 (4): 397-429.
44. Frikke-Schmidt R, Nordestgaard BG, Agerholm-Larsen B, Schnohr P, Tybjaerg-Hansen A. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res 2000: 41 (11): 1812-1822.
45. Berg K. Gene-environment interaction: variability gene concept. In: Goldbourt U, de Faire U, Berg K, eds. Genetic Factors in Coronary Heart Disease. Dordrecht/Boston/London: Kluwer Academic, 1994: 373-383.
46. Marques-Vidal P, Montaye M, Haas B et al. Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME study. J Hum Hypertens 2000: 14 (8): 511-518.
47. Hauf-Zachariou U, Widmann L, Zulsdorf B, Hennig M, Lang PD. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993: 45 (2): 95-100.
48. Staels B, Dallongeville J, Auwerx J et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998: 98 (19): 2088-2093.
49. Vu-Dac N, Schoonjans K, Kosykh V et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995: 96 (2): 741-750.
50. Chinetti G, Gbaguidi FG, Griglio S et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000: 101 (20): 2411-2417.
51. Acton S, Rigotti A, Landschulz KT et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996: 271 (5248): 518-520.
52. Ji Y, Jian B, Wang N et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997: 272 (34): 20982-20985.